You are here
Home > Investor RelationsInvestor Relations
|
Featured Event
|
|||
|
4:30 PM ET |
OncoGenex First Quarter 2013 Conference Call
|
||
OncoGenex Pharmaceuticals is a drug discovery and development company uniquely focused on the challenge of cancer treatment resistance.
Role of Hsp27 and OGX-427 Mechanism of Action Video
Stock quote (NASDAQ: OGXI)
Price: 10.50 Change: + 0.08 Volume 84,500
4:00 PM ET on May 17, 2013
Delayed at least 20 minutes. Provided by eSignal.
|
Webcasts & Presentations
|
|||
|
May 2, 2013
4:30 PM ET |
OncoGenex First Quarter 2013 Conference Call | Listen to webcast | |
|---|---|---|---|
|
Apr 5, 2013
9:30 AM ET |
Future Leaders in the Biotech Industry Conference | Listen to webcast |
View Presentation
1.7 MB
|
|
Mar 7, 2013
4:30 PM ET |
OncoGenex Fourth Quarter 2012 Conference Call | Listen to webcast | |
About OncoGeneX
For Patients
For Physicians
For Investors
Careers With Us
Investors
SHAREHOLDER TOOLS

© 2004-2011 OncoGenex Pharmaceuticals Inc. All rights reserved.
OncoGenex product candidates are investigational drugs for use only in approved clinical trials.
About OncoGenex
OncoGenex Pharmaceuticals is a drug discovery and development company uniquely focused on the challenge of cancer treatment resistance.
For Patients
OncoGenex is uniquely focused on the challenge of cancer treatment resistance. We currently have several on-going clinical trials that may be of interest to you.
For Physicians
OncoGenex focuses on diverse molecular entities that target mechanisms of resistance and that have the potential to re-define treatment paradigms in a variety of cancers.





